Refining Treatment Approaches for Chronic Lymphocytic Leukemia - Episode 17
Emerging Agents for R/R CLL
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, John Allan, MD, Weill Cornell Medicine, Ehab Atallah, MD, Medical College of Wisconsin, Steven Coutre, MD, Stanford University Medical Center, Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, Jennifer Woyach, MD, Ohio State University
Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Related Content:
